The deals cover development and commercialization of next-generation sequencing and digital PCR assays for minimal residual disease detection.

Northwestern Medical will begin using PathAI's AISight digital pathology image management system as part of the deal.

The BLIPI test device was used to monitor babies' immune status from a drop of whole blood and detected sepsis within 15 minutes, enabling incubator-side testing.

Of the 30 companies included in the list, 15 saw their stock prices decline, while 15 saw their share prices rise.

The RiskReveal assay was used to determine which early-stage non-squamous NSCLC patients should undergo adjuvant chemotherapy.

The envisioned flow cytometry test will help to predict patient response to immunotherapies for five cancer indications.

NEW YORK — Genedrive said on Friday that it has received CE marking under the EU's In Vitro Diagnostic Medical Device Regulation (IVDR) for its point-of-care CYP2C19 ID Kit genotyping platform, which ...

The London-based firm will provide its CIZ1B lung cancer test and DEX-G2 gastric cancer test for use in Doctors Hospital in the Cayman Islands.

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.